Ongoing research and innovative approaches, including ghrelin receptor modulators, stable PYY analogues, positive allosteric modulators for CCK, and advanced amylin analogues or DACRAs, showcase the potential for more effective and targeted anti‐obesity medications. This evidence concerns the gene CCK and obesity due to melanocortin 4 receptor deficiency.